Mike Faerm is an Interim CFO for startups at Burkland. He has extensive experience in life sciences, from the perspectives of an industry executive, equity analyst, and investment banker. Mike has developed and implemented strategy for a broad range of companies and has executed a wide variety of transactions including IPOs and other equity financings, debt financings, nondilutive structured funding, M&As, and licensing agreements.
Mike was the Chief Business Officer for Innoviva, a pharmaceutical company, where he led all corporate development activities and advised on investor relations and strategy. In his other roles in biopharma companies, Mike worked in business development at Forest Laboratories, sourcing and executing deals with growing biotech companies to fund and develop pipeline programs. Mike also worked at Regeneron Pharmaceuticals, performing long-term financial planning and helping execute a collaboration agreement for the company’s largest product, Eylea.
Prior to this, Mike worked at Wells Fargo and at Credit Suisse, covering stocks in the pharmaceutical industry. In this role, Mike performed in-depth strategic and financial analyses of companies, made investment recommendations, and interacted extensively with company management teams and investors. Previously as an investment banker at Merrill Lynch, Mike executed a wide range of transactions, across all sectors of healthcare including biotech, pharmaceuticals, medical devices, payers, and providers.
Mike holds a Master of Business Administration from Harvard Business School, a Master of Science in Civil Engineering, with Stanford Dean’s Fellowship from Stanford University, and a Bachelor of Science in Civil Engineering, with Honors with Distinction from Columbia University.
As an Interim CFO for startups at Burkland, Mike provides CFO services to businesses working in the area of life sciences.